Alexion’s Bell Notes The Changing Role Of Innovation In Regulatory Decisions
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO of the ultra-rare disease focused biotech spoke about the challenges of launching a drug for a relatively unknown disease and how innovation is playing an increasing role in R&D.
You may also be interested in...
Alexion Pumps Up Its Rare Disease Portfolio With Enobia Acquisition
Alexion could pay as much as $1.08 billion for access to Enobia's mid-stage rare disease compound asfotase alpha.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.